The Experts below are selected from a list of 1728 Experts worldwide ranked by ideXlab platform

Shigemasa Kudo - One of the best experts on this subject based on the ideXlab platform.

  • 2108 Blood Group antigen targeting peptide suppresses anti Blood Group Antibody binding to antigen in renal glomerular capillaries after abo incompatible Blood reperfusion
    The Journal of Urology, 2013
    Co-Authors: Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Hayato Yamamoto, Kengo Imanishi, Teppei Okamoto, Noriko Tokui, Naoki Sugiyama, Yuichiro Suzuki, Shigemasa Kudo
    Abstract:

    transporter (NKCC2) in TAL cells and failure of THP KO mice to respond to furosemide (which targets NKCC2). In contrast, old THP KO mice had significantly less 24-hour urine volume and higher urine super-saturation than age-matched wild-type controls. Serum cystatin C was significantly higher and inulin and creatinine clearance was significantly lower in old THP KO mice than in old wild-type controls, suggesting reduced GFR in the old THP KO mice. While old THP KO remained unresponsive to furosemide, they were highly responsive to acetazolamide, suggesting a compensatory increase of water reabsorption by PCT in old THP KO mice. CONCLUSIONS: A marked decrease of GFR and a compensatory increase of water reabsorption in PCT triggered by a TAL-PCT crosstalk lead to low urine volume and supersaturation of urine constituents including hydroxyapatite in the THP KO mice, thus forming the basis of age-dependent intra-renal calcinosis.

  • Blood Group antigen-targeting peptide suppresses anti-Blood Group Antibody binding to antigen in renal glomerular capillaries after ABO-incompatible Blood reperfusion.
    Transplantation Journal, 2013
    Co-Authors: Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Hayato Yamamoto, Kengo Imanishi, Teppei Okamoto, Noriko Tokui, Naoki Sugiyama, Yuichiro Suzuki, Shigemasa Kudo
    Abstract:

    BACKGROUND Antibody-mediated rejection after ABO-incompatible kidney transplantation (ABO-I KTx) is a major barrier to transplantation success. The advent of immunosuppressive therapy has markedly improved graft survival in ABO-I KTx. However, compared with normal KTx, clinical conditions during ABO-I KTx are difficult to control because of overimmunosuppression. To reduce the need for immunosuppression, we aimed to develop a novel Blood Group antigen-neutralizing therapy. METHODS We screened for an ABO Blood Group antigen-targeting peptide (BATP) by screening of T7 phage-displayed peptide library. After screening, hemagglutination inhibition assays, enzyme-linked immunosorbent assay, and cytotoxicity assay were used to analyze the Blood Group antigen-blocking effect and toxicity of BATP. We also tested the inhibitory effects on anti-Blood Group Antibody binding in normal human kidney tissues blocked with BATP and excised kidneys perfused ex vivo with BATP. RESULTS We identified six peptide sequences that efficiently suppressed hemagglutination of red Blood cells by anti-ABO Blood Group antibodies and binding of these antibodies to ABO histo-Blood Group antigens in kidney tissues. Surprisingly, ex vivo perfusion of BATP in kidneys excised from renal cell carcinoma patients caused significant suppression of anti-Blood Group Antibody binding to antigen and IgG and IgM deposition in renal glomerular capillaries after ABO-I Blood reperfusion. CONCLUSIONS These data indicate that A/B Blood Group antigens on red Blood cells and in kidney tissues may be neutralized by BATP. This approach may enable the development of a novel Blood Group antigen-neutralizing therapy to overcome the challenges of ABO-I KTx.

Tohru Yoneyama - One of the best experts on this subject based on the ideXlab platform.

  • 2108 Blood Group antigen targeting peptide suppresses anti Blood Group Antibody binding to antigen in renal glomerular capillaries after abo incompatible Blood reperfusion
    The Journal of Urology, 2013
    Co-Authors: Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Hayato Yamamoto, Kengo Imanishi, Teppei Okamoto, Noriko Tokui, Naoki Sugiyama, Yuichiro Suzuki, Shigemasa Kudo
    Abstract:

    transporter (NKCC2) in TAL cells and failure of THP KO mice to respond to furosemide (which targets NKCC2). In contrast, old THP KO mice had significantly less 24-hour urine volume and higher urine super-saturation than age-matched wild-type controls. Serum cystatin C was significantly higher and inulin and creatinine clearance was significantly lower in old THP KO mice than in old wild-type controls, suggesting reduced GFR in the old THP KO mice. While old THP KO remained unresponsive to furosemide, they were highly responsive to acetazolamide, suggesting a compensatory increase of water reabsorption by PCT in old THP KO mice. CONCLUSIONS: A marked decrease of GFR and a compensatory increase of water reabsorption in PCT triggered by a TAL-PCT crosstalk lead to low urine volume and supersaturation of urine constituents including hydroxyapatite in the THP KO mice, thus forming the basis of age-dependent intra-renal calcinosis.

  • Blood Group antigen-targeting peptide suppresses anti-Blood Group Antibody binding to antigen in renal glomerular capillaries after ABO-incompatible Blood reperfusion.
    Transplantation Journal, 2013
    Co-Authors: Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Hayato Yamamoto, Kengo Imanishi, Teppei Okamoto, Noriko Tokui, Naoki Sugiyama, Yuichiro Suzuki, Shigemasa Kudo
    Abstract:

    BACKGROUND Antibody-mediated rejection after ABO-incompatible kidney transplantation (ABO-I KTx) is a major barrier to transplantation success. The advent of immunosuppressive therapy has markedly improved graft survival in ABO-I KTx. However, compared with normal KTx, clinical conditions during ABO-I KTx are difficult to control because of overimmunosuppression. To reduce the need for immunosuppression, we aimed to develop a novel Blood Group antigen-neutralizing therapy. METHODS We screened for an ABO Blood Group antigen-targeting peptide (BATP) by screening of T7 phage-displayed peptide library. After screening, hemagglutination inhibition assays, enzyme-linked immunosorbent assay, and cytotoxicity assay were used to analyze the Blood Group antigen-blocking effect and toxicity of BATP. We also tested the inhibitory effects on anti-Blood Group Antibody binding in normal human kidney tissues blocked with BATP and excised kidneys perfused ex vivo with BATP. RESULTS We identified six peptide sequences that efficiently suppressed hemagglutination of red Blood cells by anti-ABO Blood Group antibodies and binding of these antibodies to ABO histo-Blood Group antigens in kidney tissues. Surprisingly, ex vivo perfusion of BATP in kidneys excised from renal cell carcinoma patients caused significant suppression of anti-Blood Group Antibody binding to antigen and IgG and IgM deposition in renal glomerular capillaries after ABO-I Blood reperfusion. CONCLUSIONS These data indicate that A/B Blood Group antigens on red Blood cells and in kidney tissues may be neutralized by BATP. This approach may enable the development of a novel Blood Group antigen-neutralizing therapy to overcome the challenges of ABO-I KTx.

Yuichiro Suzuki - One of the best experts on this subject based on the ideXlab platform.

  • 2108 Blood Group antigen targeting peptide suppresses anti Blood Group Antibody binding to antigen in renal glomerular capillaries after abo incompatible Blood reperfusion
    The Journal of Urology, 2013
    Co-Authors: Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Hayato Yamamoto, Kengo Imanishi, Teppei Okamoto, Noriko Tokui, Naoki Sugiyama, Yuichiro Suzuki, Shigemasa Kudo
    Abstract:

    transporter (NKCC2) in TAL cells and failure of THP KO mice to respond to furosemide (which targets NKCC2). In contrast, old THP KO mice had significantly less 24-hour urine volume and higher urine super-saturation than age-matched wild-type controls. Serum cystatin C was significantly higher and inulin and creatinine clearance was significantly lower in old THP KO mice than in old wild-type controls, suggesting reduced GFR in the old THP KO mice. While old THP KO remained unresponsive to furosemide, they were highly responsive to acetazolamide, suggesting a compensatory increase of water reabsorption by PCT in old THP KO mice. CONCLUSIONS: A marked decrease of GFR and a compensatory increase of water reabsorption in PCT triggered by a TAL-PCT crosstalk lead to low urine volume and supersaturation of urine constituents including hydroxyapatite in the THP KO mice, thus forming the basis of age-dependent intra-renal calcinosis.

  • Blood Group antigen-targeting peptide suppresses anti-Blood Group Antibody binding to antigen in renal glomerular capillaries after ABO-incompatible Blood reperfusion.
    Transplantation Journal, 2013
    Co-Authors: Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Hayato Yamamoto, Kengo Imanishi, Teppei Okamoto, Noriko Tokui, Naoki Sugiyama, Yuichiro Suzuki, Shigemasa Kudo
    Abstract:

    BACKGROUND Antibody-mediated rejection after ABO-incompatible kidney transplantation (ABO-I KTx) is a major barrier to transplantation success. The advent of immunosuppressive therapy has markedly improved graft survival in ABO-I KTx. However, compared with normal KTx, clinical conditions during ABO-I KTx are difficult to control because of overimmunosuppression. To reduce the need for immunosuppression, we aimed to develop a novel Blood Group antigen-neutralizing therapy. METHODS We screened for an ABO Blood Group antigen-targeting peptide (BATP) by screening of T7 phage-displayed peptide library. After screening, hemagglutination inhibition assays, enzyme-linked immunosorbent assay, and cytotoxicity assay were used to analyze the Blood Group antigen-blocking effect and toxicity of BATP. We also tested the inhibitory effects on anti-Blood Group Antibody binding in normal human kidney tissues blocked with BATP and excised kidneys perfused ex vivo with BATP. RESULTS We identified six peptide sequences that efficiently suppressed hemagglutination of red Blood cells by anti-ABO Blood Group antibodies and binding of these antibodies to ABO histo-Blood Group antigens in kidney tissues. Surprisingly, ex vivo perfusion of BATP in kidneys excised from renal cell carcinoma patients caused significant suppression of anti-Blood Group Antibody binding to antigen and IgG and IgM deposition in renal glomerular capillaries after ABO-I Blood reperfusion. CONCLUSIONS These data indicate that A/B Blood Group antigens on red Blood cells and in kidney tissues may be neutralized by BATP. This approach may enable the development of a novel Blood Group antigen-neutralizing therapy to overcome the challenges of ABO-I KTx.

Naoki Sugiyama - One of the best experts on this subject based on the ideXlab platform.

  • 2108 Blood Group antigen targeting peptide suppresses anti Blood Group Antibody binding to antigen in renal glomerular capillaries after abo incompatible Blood reperfusion
    The Journal of Urology, 2013
    Co-Authors: Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Hayato Yamamoto, Kengo Imanishi, Teppei Okamoto, Noriko Tokui, Naoki Sugiyama, Yuichiro Suzuki, Shigemasa Kudo
    Abstract:

    transporter (NKCC2) in TAL cells and failure of THP KO mice to respond to furosemide (which targets NKCC2). In contrast, old THP KO mice had significantly less 24-hour urine volume and higher urine super-saturation than age-matched wild-type controls. Serum cystatin C was significantly higher and inulin and creatinine clearance was significantly lower in old THP KO mice than in old wild-type controls, suggesting reduced GFR in the old THP KO mice. While old THP KO remained unresponsive to furosemide, they were highly responsive to acetazolamide, suggesting a compensatory increase of water reabsorption by PCT in old THP KO mice. CONCLUSIONS: A marked decrease of GFR and a compensatory increase of water reabsorption in PCT triggered by a TAL-PCT crosstalk lead to low urine volume and supersaturation of urine constituents including hydroxyapatite in the THP KO mice, thus forming the basis of age-dependent intra-renal calcinosis.

  • Blood Group antigen-targeting peptide suppresses anti-Blood Group Antibody binding to antigen in renal glomerular capillaries after ABO-incompatible Blood reperfusion.
    Transplantation Journal, 2013
    Co-Authors: Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Hayato Yamamoto, Kengo Imanishi, Teppei Okamoto, Noriko Tokui, Naoki Sugiyama, Yuichiro Suzuki, Shigemasa Kudo
    Abstract:

    BACKGROUND Antibody-mediated rejection after ABO-incompatible kidney transplantation (ABO-I KTx) is a major barrier to transplantation success. The advent of immunosuppressive therapy has markedly improved graft survival in ABO-I KTx. However, compared with normal KTx, clinical conditions during ABO-I KTx are difficult to control because of overimmunosuppression. To reduce the need for immunosuppression, we aimed to develop a novel Blood Group antigen-neutralizing therapy. METHODS We screened for an ABO Blood Group antigen-targeting peptide (BATP) by screening of T7 phage-displayed peptide library. After screening, hemagglutination inhibition assays, enzyme-linked immunosorbent assay, and cytotoxicity assay were used to analyze the Blood Group antigen-blocking effect and toxicity of BATP. We also tested the inhibitory effects on anti-Blood Group Antibody binding in normal human kidney tissues blocked with BATP and excised kidneys perfused ex vivo with BATP. RESULTS We identified six peptide sequences that efficiently suppressed hemagglutination of red Blood cells by anti-ABO Blood Group antibodies and binding of these antibodies to ABO histo-Blood Group antigens in kidney tissues. Surprisingly, ex vivo perfusion of BATP in kidneys excised from renal cell carcinoma patients caused significant suppression of anti-Blood Group Antibody binding to antigen and IgG and IgM deposition in renal glomerular capillaries after ABO-I Blood reperfusion. CONCLUSIONS These data indicate that A/B Blood Group antigens on red Blood cells and in kidney tissues may be neutralized by BATP. This approach may enable the development of a novel Blood Group antigen-neutralizing therapy to overcome the challenges of ABO-I KTx.

Noriko Tokui - One of the best experts on this subject based on the ideXlab platform.

  • 2108 Blood Group antigen targeting peptide suppresses anti Blood Group Antibody binding to antigen in renal glomerular capillaries after abo incompatible Blood reperfusion
    The Journal of Urology, 2013
    Co-Authors: Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Hayato Yamamoto, Kengo Imanishi, Teppei Okamoto, Noriko Tokui, Naoki Sugiyama, Yuichiro Suzuki, Shigemasa Kudo
    Abstract:

    transporter (NKCC2) in TAL cells and failure of THP KO mice to respond to furosemide (which targets NKCC2). In contrast, old THP KO mice had significantly less 24-hour urine volume and higher urine super-saturation than age-matched wild-type controls. Serum cystatin C was significantly higher and inulin and creatinine clearance was significantly lower in old THP KO mice than in old wild-type controls, suggesting reduced GFR in the old THP KO mice. While old THP KO remained unresponsive to furosemide, they were highly responsive to acetazolamide, suggesting a compensatory increase of water reabsorption by PCT in old THP KO mice. CONCLUSIONS: A marked decrease of GFR and a compensatory increase of water reabsorption in PCT triggered by a TAL-PCT crosstalk lead to low urine volume and supersaturation of urine constituents including hydroxyapatite in the THP KO mice, thus forming the basis of age-dependent intra-renal calcinosis.

  • Blood Group antigen-targeting peptide suppresses anti-Blood Group Antibody binding to antigen in renal glomerular capillaries after ABO-incompatible Blood reperfusion.
    Transplantation Journal, 2013
    Co-Authors: Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Hayato Yamamoto, Kengo Imanishi, Teppei Okamoto, Noriko Tokui, Naoki Sugiyama, Yuichiro Suzuki, Shigemasa Kudo
    Abstract:

    BACKGROUND Antibody-mediated rejection after ABO-incompatible kidney transplantation (ABO-I KTx) is a major barrier to transplantation success. The advent of immunosuppressive therapy has markedly improved graft survival in ABO-I KTx. However, compared with normal KTx, clinical conditions during ABO-I KTx are difficult to control because of overimmunosuppression. To reduce the need for immunosuppression, we aimed to develop a novel Blood Group antigen-neutralizing therapy. METHODS We screened for an ABO Blood Group antigen-targeting peptide (BATP) by screening of T7 phage-displayed peptide library. After screening, hemagglutination inhibition assays, enzyme-linked immunosorbent assay, and cytotoxicity assay were used to analyze the Blood Group antigen-blocking effect and toxicity of BATP. We also tested the inhibitory effects on anti-Blood Group Antibody binding in normal human kidney tissues blocked with BATP and excised kidneys perfused ex vivo with BATP. RESULTS We identified six peptide sequences that efficiently suppressed hemagglutination of red Blood cells by anti-ABO Blood Group antibodies and binding of these antibodies to ABO histo-Blood Group antigens in kidney tissues. Surprisingly, ex vivo perfusion of BATP in kidneys excised from renal cell carcinoma patients caused significant suppression of anti-Blood Group Antibody binding to antigen and IgG and IgM deposition in renal glomerular capillaries after ABO-I Blood reperfusion. CONCLUSIONS These data indicate that A/B Blood Group antigens on red Blood cells and in kidney tissues may be neutralized by BATP. This approach may enable the development of a novel Blood Group antigen-neutralizing therapy to overcome the challenges of ABO-I KTx.